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Role of pathology indices in the management of severe lupus glomeru-
lonephritis. The principal value of the renal biopsy in patients with SLE
is as a therapeutic guide. Although semiquantitative indices of nephron
loss (chronicity = CI) and acute potentially reversible inflammation(activity = Al) are reported by some to have separate values from
traditional classifications of glomerular pathology as predictors of
outcome and therapeutic guides, this point remains controversial. We
have tested the predictive value of the Al and CI in a large group of
patients with severe lupus glomerulonephritis (SLE GN) and a mean
follow-up of 281 weeks 116 (mean SD). A total of 86 patients
entered into the study of plasmapheresis in severe SLE GN by the
Lupus Nephritis Collaborative Study Group, and long-term follow-up
was available in 83. The predictive value of the Al and the CI was
described over the entire range of cut-off points by the method of
receiver operator characteristics (ROC). ROC analysis demonstrated
that there was no level of either Al or CI that predicted the outcome of
death or renal failure with sufficient sensitivity and specificity to be
useful in the individual patient. The CI signifies renal damage and
nephron loss, whereas the Al describes potentially reversible pathol-
ogy. Neither the CI nor the A! taken by itself predicts individual
outcomes of renal failure or death in patients with aggressively treated
SLE GN. Since the indices fail to identify the patient whose disease will
progress to renal failure, they are both insufficient as therapeutic guides
and add little to the management of the patient with severe SLE GN.
The renal pathology of systemic lupus erythematosus (SLE),
as demonstrated by renal biopsy, is related to patient survival
and preservation of renal function [1—4]. The attempt to identify
patients early in the course of SLE, who ultimately develop
progressive renal insufficiency despite optimal therapy, has led
the search for parameters which might refine the predictive
value of the International Study of Kidney Disease in Children/
World Health Organization (ISKDC/WHO) histological classi-
fication [6]. Because current treatment has significantly im-
proved the short-term prognosis for patients with diffuse SLE
GN [5] and because the majority of patients with diffuse SLE
GN do not die or progress to renal failure, pathological indices
of disease activity (Al) and chronicity (CI) have been defined in
an attempt to utilize biopsy information not addressed by the
ISKDC/WHO classification [7, 8]. The Al and CI are derived
using a scoring system first described by Pirani et al [9] and
subsequently modified by Morel-Maroger et al [10]. While a
great deal has been written which implies that the A! or CI may
have strong prognostic inference, the predictive value of these
parameters remains the subject of controversy, as reviewed by
Esdaile et al [11]. Previously, we evaluated the Al and the CI in
a large group of patients who were followed for a mean of 109
74 weeks (mean SD) [12] and were unable to confirm
predictive values for the A! or CI. Austin et al [7, 8] demon-
strated that a relation between CI and renal failure became
apparent only after 53 and 61 months of follow-up. To test the
effect of a comparable, prolonged follow-up on the predictive
value of the Al and CI, we present herein the analysis of our
patients more than five years after renal biopsy.
Methods
Patients
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The 83 patients in this analysis were from the study of
plasmapheresis in severe lupus nephritis undertaken by the
Lupus Nephritis Collaborative Study Group (LNCSG). The
detailed pathologic description of the biopsies [13] and the
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clinical features and response to therapy [51 are reported
elsewhere. The patients were 32.1 12.5 years old (mean
SD), and the male/female ratio was 14/69 (83% female). Sixty-
four percent were Caucasian; 22% were Black, and 8% were
Hispanic. The patients had clinical evidence of renal involve-
ment for 13.6 27.35 months prior to biopsy. The diastolic
blood pressure was 88 13 mm FIg; the serum creatinine was
179 111 tmol/ml. The serum C3 was 57 29 mgldl; and the
urine protein excretion was 5.5 4.2 g/24 hours. In all, a total
of 45 demographic features, historical therapeutic details, phys-
ical findings, and laboratory data were analyzed for the stan-
dard and the standard plus plasmapheresis groups, and they
were similar in all respects [5, 12, 13].
Study entry required a diagnosis of SLE conforming to the
criteria of the American Rheumatism Association [141, clinical
evidence of renal disease, the absence of defined exclusion
criteria [6, 12, 13], and a biopsy diagnosis of severe lupus GN
(see below). The 86 patients who met the admission criteria
were randomized to either standard treatment or standard
treatment plus plasmapheresis to assess the clinical effect of
plasmapheresis in severe lupus GN. Since plasmapheresis did
not alter the prognosis with respect to survival, development of
renal failure, or the appearances or outcome of severe life-
threatening complications [5], we combined the standard ther-
apy and standard therapy plus plasmapheresis therapeutic
groups for the purpose of morphological analysis [12, 131. Study
entry and analysis began at the time of randomization, and the
length of follow-up ranged from five to 428 weeks with a mean
of 281 weeks 116 (mean SD). Three patients were lost to
follow-up, but only one was known to have reached renal
failure. Thus, the sample size was adjusted accordingly for each
outcome.
Renal pathology
The Central Pathology Laboratory received histological
slides, representative fluorescence photomicrographs, and elec-
tron micrographs that had been used by the clinic pathologist to
determine eligibility. The details have been previously reported
[12, 13]. The morphological material was coded in the Central
Pathology Laboratory so the pathologists scoring the biopsies
would not have direct knowledge of the clinic laboratories or of
their pathologic diagnoses.
The biopsies were classified according to a modification of
the ISKDC/WHO classification of SLE GN [6]. As reported
previously [13], the diagnosis of severe SLE GN was estab-
lished by a diagnosis of diffuse or severe focal (active or
necrotizing lesions in 50% of glomeruli) proliferative SLE
GN, with or without changes of membranous nephropathy.
Thus, three discrete morphologic categories of SLE GN were
included in the definition of severe SLE ON [13]: (1) severe
segmental GN; (2) diffuse GN; and (3) membranous GN with
either severe segmental or diffuse ON. The published criteria
for scoring the Al/Cl were followed [7, 8, 12]. The following
features were scored on the basis of the percentage of total
glomeruli involved (less than 25% 1+; 25 to 50% 2+; and >50%
3+): glomerular cell proliferation, karyorrhexis and fibrinoid
necrosis, cellular crescents, hyaline deposits (wire loops and
hyaline thrombi), glomerular sclerosis, and fibrous crescents.
Leukocyte exudation was scored on the number of neutrophils/
glomerulus, (2/glomerulus 1+; 3/glomerulus 2+; 4 or more/
glomerulus 3+). Interstitial inflammation, tubular atrophy, and
interstitial fibrosis were scored as mild (<20% 1+), moderate
(20 to 40% 2+) or severe (>40% 3+) based on the proportion of
cortical tissue involved. The At and CI were the sum of the
scores of the individual pathological features except for fibrin-
oid necrosis and cellular crescents which were weighted (score
x 2). The A! was thus defined as the sum of the scores for
glomerular proliferation, leukocyte exudation, karyorrhexis
and fibrinoid necrosis (x 2), cellular crescents (X 2), hyaline
deposits and interstitial inflammation. The maximum score for
the Al was 24 points. The CI was the sum of glomerular
sclerosis, fibrous crescents, tubular atrophy, and interstitial
fibrosis. The maximum score for the CI was 12 points.
The eligibility of the patient for entry into the study, based on
the renal pathology, was determined by the individual clinic
pathologist, but histologic stratification and scoring of the A!
and CI were accomplished by the Pathology Reading Commit-
tee (PRC). Evaluation of Al/Cl in relation to outcome and
pathologic diagnosis is based upon the mean score of four
observers (MMS, JB, GSH, KH).
Outcomes
In this analysis only two adverse outcomes were recognized:
chronic renal failure (serum creatinine 6.0 mg/dl or a rise in
serum creatinine of >3.0 mg/dl from study entry) and death
(due to renal and non-renal causes). Any patient who had not
reached renal failure or died as of January 1990 is considered as
having a "good outcome". Severe acute glomerular involve-
ment appears to be a marker for the severity of systemic disease
in SLE. It is recognized that lhe severity of lupus glomerulo-
nephritis correlates with the incidence of death from any cause.
However, we have elected to study parameters related to the
glomerular pathology with emphasis upon the outcome of renal
failure.
Statistics
The A! and Cl for patients with and without specific out-
comes were compared by the Wilcoxon 2-sample rank-sum test
[15]. The proportions of events are compared using the chi-
square statistic, with the appropriate degree of freedom [16].
Sensitivity and specificity were determined from a series of 2 x
2 tables in which the binary outcome variable (renal failure/no
renal failure; death/no death) is one classification and activity or
chronicity dichotomized by a cutoff point is the second classi-
fication. In this analysis the 2 x 2 tables for each value of the
test allow the calculation of a chi-square statistic [16]. When the
specificity and sensitivity of each test value are plotted (ordi-
nate = sensitivity and abscissa = 1 — specificity), the resulting
receiver operator characteristics (ROC) curve describes the
diagnostic efficacy of the test [17, 181. A two sided P value of
<0.05 is considered significant.
Results
Predictive value of the Al and CI for study outcomes
The entire range (range = 0 to 10) of CI scores was evaluated
for predictive ability by ROC analysis, and there was no value
of the CI that separated with satisfactory degrees of sensitivity
and specificity patients with and without either of the adverse
outcomes (Figs. 1 and 2). Despite the tendency for the CI to be
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1 -Specificity
Fig. 1. ROC curve of the predictive value of the CI for renal failure.
For low values of the CI, sensitivity is low and specificity is high. At
high values of the CI, sensitivity is high and specificity is low. The
straight line between these extremes indicates that there is no value for
the CI with sufficient sensitivity and specificity to constitute a satisfac-
tory test to separate patients with and without renal failure.
1.2
0.2 0.4 0.6 0.8
1 -Specificity
Fig. 2. ROC curve of the predictive value of the CI for death. There is
no value of the CI with sufficient sensitivity and specificity to separate
patients who died from these who survived.
higher in patients who died or reached renal failure (Table 1), it
did not predict outcome in the individual patient. Even using
cutoff points, which have been previously reported to have
graded predictive value [8], Table 2 shows that there are a
significant number of individuals at any of these values who
reach the outcome but fall below the test score (false negatives).
Conversely, many patients survive with scores greater than the
cutoffs (false positives). In the example given in Table 2, renal
failure occurred in only 3 of 19 patients with a CI I, but
two-thirds of the patients with a CI  1 did not go into renal
failure. Thus, the CI was of little value in predicting the
outcome in an individual patient.
N
Chronicity index
(mean SE) P valuea
Renal failure
no
yes
59
24
3.34 0.24
3.97 0.39 0.18
Death
no
yes
65
18
3.23 0.22
4.56 0.48 002b
a By the Wilcoxon rank-sum test
b Significant at P  0.05 level
Table 2. Chronicity index (CI) by patient outcomes using CI of  1, 2
or 3, and 4 as cutoffs
Reached
Outcome
Survived
(N)
outcome
(N) P valu&'
Renal failure1 16 3
2or3 21 9 0.33
4 22 12
Deathl 17 2
2or3 26 4 0.08
4 22 11
a By the chi-square statistic (df-2), significant at
0.2
P 0.05 level
0.0 — . . I I I
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Fig. 3. Roc curve of the predictive value of Al for renal failure.
Although sensitivity rises with increasing AL, the specificity drops.
There is no value of the At with both high sensitivity and specificity.
Thus, it is not a satisfactory test for the patient outcome of renal failure.
>,
>
C
a)
Cl)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
B
Table 1. Chronicity index summarized by patient outcomes
U
B
0.0 0.2 0.4 0.6 0.8 1.0
>
U)C
a)
C/)
0
0
0
B
1.0
0.8
0.6
0.4
0.2•
0.0
0
0
B
1.2
1.0
0.8
0.6
0.4
0.0
B BB
>
C/)C
a)
C')
B
U
B
1.0
B
B
U
B
1.0
The entire range of the Al (range = 4—22) was evaluated for
predictive value of renal failure and death by ROC analysis, and
there was no value that separated those with and those without
renal failure (Fig. 3) or the dead from the survivors (not
illustrated). Also, the mean value of Al did not differentiate
patients with the study outcomes of death and renal failure from
the survivors (Table 3). When the patients were arbitrarily
divided at a score of 12 (12 < Al  12) [8], there was not a
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Table 3. Activity index summarized by patient outco
activity index SEM)
mes (mean
Activity index
N (mean SE) P valuee
Renal failure
no
yes
59 11.06±0.46
24 11.99±0.55 020.
Death
no
yes
65 11.46±0.44
18 10.86 0.55 057'
Renal failure
Al < 12
Al  12
No Yes P valuea
35 12 0.44
24 12
Death
AI<12 36 11 0.67AI12 29 7
a By the chi-square statistic, significant at the P 0.05 level
graded predictive value for the higher scores for either of the
adverse outcomes (Table 4).
Relationship of histological components of Cl and Al to
study outcomes
The mean CI was not predictive of outcome for the group
who went into renal failure, but glomerular sclerosis, a histo-
logical component of the CI, was related to renal failure (P
0.04). Conversely, although the mean CI was elevated in those
patients who died (Table 1), none of the individual histological
components of the CI predicted death. None of the histological
components of the Al was related to either death or renal
failure.
Relationship of Cl and Al stratified by pathologic category to
patient outcome
There were 26 patients with membranous GN plus superim-
posed severe segmental or diffuse GN. Although this histolog-
ical category has been previously shown to have the worst
prognosis of all the three different lesions that constitute severe
lupus GN [13], neither the mean CI nor the mean Al was greater
in either the group of patients who developed renal failure
(Tables 5 and 6) or died (data not given) compared to those who
survived. In this group, crescents, a component of the Al, were
more frequent in patients who went into renal failure (P =0.01).
None of the other components of the Al or of the CI were
related to either study outcome.
The CI, the Al and their histological components were not
related to either renal failure (Tables 5 and 6) or death (data not
given) in the 35 patients with diffuse GN and the 22 patients
with severe segmental GN.
Discussion
It has been proposed that semiquantitative histological indi-
ces of acute and chronic renal pathology are better predictors of
outcome in SLE GN than the ISKDC/WHO classification of
Pathology category
No renal
failure (N)
Renal
failure
P
(N) valuea
Membranous UN 3,83 0.47 (16) 4.32 0.71 (11) 0.64
plus severe segmental
or diffuse GN
Severe segmental GN 2.79 0.38 (28) 3.43 0.84 (7) 0.55
Diffuse GN 3.85 0.35 (15) 4.11 0.56 (11) 0,84
Pathology category
No renal
failure (N)
Renal
failure
P
(N) valuee
Membranous UN 9.44 0.68 (16) 12.24 1.04 (6) 0.06
plus severe segmental
or diffuse GN
Severe segmental GN 12.61 0.65 (28) 12.43 1.12 (7) 0.99
Diffuse GN 9.88 0.92 (15) 11.57 0.86 (11) 0.21
lupus glomerulonephritis [7, 8]. In their initial report, Decker et
al [19] determined the A! and CI from the renal biopsies of a
large group of SLE patients with a broad spectrum of glomer-
ular pathology, and the patients with the highest total pathology
score (Al + CI) had the most profound depression of renal
function both at the time of biopsy and after two years of
follow-up. This study was criticized because of the good
prognosis of the relatively benign forms of lupus GN which
were included [201. However, in studies by five different groups
of investigators restricted to biopsies showing the most widely
distributed inflammatory lesions (diffuse proliferative and mem-
branoproliferative GN), the patients who developed renal fail-
ure had a higher Al and/or CI in their initial biopsies compared
to the group that did not develop renal failure [7, 8, 11, 12, 21,
22]. These retrospective studies establish that lupus patients
with permanent nephron loss and concurrent glomerular inflam-
mation are more likely to experience further loss of renal
function than patients with similar glomerular inflammation and
no scarring. While trends were identified for defined groups of
patients, it must be emphasized that these predictable results
did not prospectively identify which patients ultimately devel-
oped renal failure.
The presence of any of the histological features of the CI (CI
 1) reportedly defines patients at risk of developing renal
failure [8]. Unfortunately, the sensitivity and specificity of the
CI, using a score of 1 to separate patients with a good and poor
prognosis, are not clinically useful. In fact, when any value of
the CI score is used as a cutoff [8, 12], there are too many
patients who either have the requisite score but do not develop
renal failure (false positives) or whose scores do not reach the
cutoff but develop renal failure (false negatives). The CI will be
a useful clinical test only if one is able to define a value of the
CI that predicts the outcome of renal failure with high specific-
ity and sensitivity.
ROC analysis [17, 18] was developed to analyze tests that
report their result as a numerical score. Using this approach,
Table 5. Chronicity index summarized by patient outcome of renal
failure and pathology category (mean SE)
a By the Wilcoxon rank-sum test, significant at the P 0.05 level
Table 4. Activity index (Al) by patient outcomes using a value of Al
a 12 as the cutoff
a By the Wilcoxon rank-sum test, significant at the P 0.05 level
Table 6, Activity summarized by the patient outcome of of renal
failure and pathology category (mean 5EM)
a By the Wilcoxon rank-sum test, significant at the P 0.05
Schwartz et al. Pathology indices in lupus nephritis 747
one can determine the score that optimally separates those who
will or will not develop renal failure. ROC analysis calculates
the specificity and sensitivity of the test for every score and
graphically displays the results. A test that separates those with
the disease (in this case, renal failure) from those who do not
have the disease should have a curve that rises rapidly at the
critical score (indicating concurrent high sensitivity and speci-
ficity) and plateaus for all subsequent values (indicating high
sensitivity and decreasing specificity). When we applied ROC
analysis to the chronicity index in the present study, the shape
of the curve implied that for any test score, the chance of
developing or not developing renal failure is about the same.
This is the result we reported initially after approximately two
years of follow-up [121. We repeated the analysis because in
lupus GN more cases of renal failure develop after five years of
follow-up [7], and by increasing the number of cases reaching
renal failure, we hoped to increase the power of the test. Since
the patients studied by Austin et al [7, 8] were observed for a
total of 79 months (26 months clinically evident nephritis prior
to biopsy and 53 months median follow-up), the 83.6 months of
observation in our study (13.6 months of renal involvement
pre-biopsy and 70 months (mean follow-up) should have pro-
vided an adequate test of the pathologic indices as predictors of
renal failure. However, the results of the current and initial
analysis are almost identical. Neither the A! nor the CI identi-
fies which patient will develop renal failure.
The CI has also been used to assess therapy [23, 24], and
these studies imply that it should be used as therapeutic guide.
The CI was initially used to construct a statistical model that
predicted time to renal failure [7]. When treatment was incor-
porated into the model, the results suggested that "immuno-
suppressive agents provide a slight therapeutic advantage over
oral corticosteroids alone". This conclusion was reached by the
dubious statistical maneuver of combining four different immu-
nosuppressive regimens, but the point is moot because the
result was not statistically significant. Serial biopsies in a
subgroup of the same patients with diffuse proliferative or
membranoproliferative GN [231 suggested that there was more
glomerular sclerosis in the follow-up biopsies of patients who
received prednisone alone rather than in combination with an
immunosuppressive agent. The CI was also used to analyze the
same group by defining patients at high risk of developing renal
failure, and the patients treated with intravenous cyclophospha-
mide reportedly had a significantly better outcome than those
who received high-dose prednisone alone [24]. The power of
these observations is decreased because they were obtained in
small groups of patients; the biopsies showed a variety of renal
lesions; and the patients were treated with four different immu-
nosuppressive regimens. Although the conclusions may be
disputed both on statistical grounds and because of the variabil-
ity in the therapeutic response of the different histologic forms
of lupus GN included in the study, there is a more basic
objection to using the CI as a therapeutic guide.
Renal scarring or chronicity, indicates irreversible loss of
renal parenchyma. There is no data to suggest that any current
or proposed therapeutic regimen is able to reverse the lesions
associated with chronicity, and even the proponents of the CI
[7, 8, 23, 24] do not suggest that histological signs of chronicity
are reversed by therapy. Glomerular sclerosis, glomerular
fibrous crescents, interstitial fibrosis and tubular atrophy mdi-
cate the natural history of the disease in a particular patient, but
the presence of scarred nephrons, by itself, does not imply the
need for a specific therapy. Furthermore, if one is only able to
apply the CI to patients with diffuse proliferative GN [7, 8], a
lesion that most clinicians recognize as an indication for maxi-
mum therapy on its own, the putative predictive value of the CI
adds little to the management of the individual patient.
In contrast, acute inflammation, or activity, is identified by
the presence of inflammatory cell infiltrates, immunoglobulins
and complement deposition, cellular proliferation, and signs of
necrosis. The AT presents a paradox because its histological
components are the basis for identifying active lupus GN, but in
general, it has not been found to add predictive value to the
ISKDC/WHO classification [7, 8, 12]. It seems likely that the
lack of predictive ability of the Al is a function of the respon-
siveness of the active lesions to available therapy. This is
supported by current survival of patients with severe lupus GN
who can expect a five year survival of more than 60% without
death or renal failure [5]. Esdaile et a! [11] added a kinetic
component to this interpretation by demonstrating that the
duration of renal disease before the biopsy diagnosis of severe
GN was an independent predictor of renal SLE death. They
postulate that undertreatment during this interval allows active
lesions to progress to irreversible renal damage.
The renal biopsy provides a unique assessment of the status
of the renal parenchyma in SLE patients with signs of renal
disease, and the histological information contained therein
separates those in emergent need of therapy from patients
whose histological lesions have a more benign natural history
[1—4]. Our results indicate that histological indices of activity
and chronicity are no better predictors of outcome than the
ISKDCIWHO classification of glomerular pathology in SLE
and are of little clinical value in any given patient. The chro-
nicity index should not be considered as a therapeutic guide
because it describes irretrievable nephron loss. The activity
index describes potentially responsive lesions, but until it is
demonstrated that it provides therapeutic information that is
not present in the simple reproducible histological classifica-
tion, the use of the activity index as a therapeutic guide should
also be discouraged.
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